

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

March 28, 2018

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai- 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB

Dear Sir(s),

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update on the Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited (Transferee Company) and Neuland Health Sciences Private Limited (First Transferor Company) and Neuland Pharma Research Private Limited (Second Transferor Company) and their respective Shareholders and Creditors ("Scheme")

Ref: NSE Observation Letter bearing reference no. NSE/LIST/101407 dated January 20, 2017 and BSE Observation Letter bearing reference no. DCS/AMAL/SD/R37/685/2016-17 dated January 20, 2017

We refer to the subject cited above and with further reference to the Observation letters, we wish to inform you that the Hon'ble National Company Law Tribunal ("NCLT"), Hyderabad Bench, vide its Order dated March 28, 2018, has approved the Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited (Transferee Company) and Neuland Health Sciences Private Limited (First Transferor Company) and Neuland Pharma Research Private Limited (Second Transferor Company) and their respective Shareholders and Creditors ("Scheme").

A copy of the afore-mentioned Order is being uploaded on the website of the Company, www.neulandlabs.com.

This is for your information and records.

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

